文献速递头痛与眩晕

扎维吉泮10毫克鼻喷剂用于美国偏头痛急性治疗的安全性、耐受性和疗效:一项3期、双盲、随机、安慰剂对照、多中心试验

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
PubMed 文献 · Lancet Neurol · 2023-01-01

该3期双盲随机安慰剂对照多中心试验在美国90个中心纳入1405例成人偏头痛患者,比较扎维吉泮10毫克鼻喷剂与安慰剂急性治疗单次中重度偏头痛发作的疗效。治疗2小时后,扎维吉泮组无痛率24% vs 安慰剂组15%,最困扰症状缓解率40% vs 31%,差异均具统计学显著性。常见不良事件为味觉障碍、鼻部不适和恶心,未发现肝毒性信号。

要点

  • 扎维吉泮10毫克鼻喷剂治疗2小时无痛率24% vs 安慰剂15%,风险差8.8个百分点(95%CI 4.5-13.1;p<0.0001)。
  • 最困扰症状缓解率40% vs 31%,风险差8.7个百分点(95%CI 3.4-13.9;p=0.0012)。
  • 常见不良事件为味觉障碍21% vs 5%、鼻部不适4% vs 1%、恶心3% vs 1%,未发现肝毒性信号。

核心结论

  • 扎维吉泮10毫克鼻喷剂对偏头痛急性治疗有效,耐受性和安全性良好。
  • 需要额外试验来确定长期安全性和跨发作疗效的一致性。

研究设计与样本

  • 3期、双盲、随机、安慰剂对照、多中心试验,在美国90个学术医学中心、头痛诊所和独立研究机构开展。
  • 纳入年龄≥18岁、每月有2至8次中重度偏头痛发作史的成人,按1:1随机分配至扎维吉泮10毫克鼻喷剂或匹配安慰剂,按预防性药物使用与否分层。
  • 于2020年10月27日至2021年8月20日期间招募1978例受试者评估资格,1405例合格(扎维吉泮组703例,安慰剂组702例),1269例纳入疗效分析集(扎维吉泮组623例,安慰剂组646例)。
  • 共同主要终点为治疗给药后2小时无痛和无最困扰症状,在全部随机分配、服用研究药物、基线为中重度疼痛强度且至少提供一个可评估基线后疗效数据点的参与者中评估;安全性在全部随机分配且至少接受一剂药物的参与者中分析。
  • 试验注册号ClinicalTrials.gov NCT04571060,已停止招募。

主要发现

  • 治疗2小时后,扎维吉泮组无痛147例(24%)/623例 vs 安慰剂组96例(15%)/646例,风险差8.8个百分点(95%CI 4.5-13.1;p<0.0001)。
  • 治疗2小时后,扎维吉泮组最困扰症状缓解247例(40%)vs 安慰剂组201例(31%),风险差8.7个百分点(95%CI 3.4-13.9;p=0.0012)。
  • 任一治疗组最常见不良事件(≥2%)为味觉障碍(扎维吉泮组129例[21%]/629例 vs 安慰剂组31例[5%]/653例)、鼻部不适(23例[4%] vs 5例[1%])和恶心(20例[3%] vs 7例[1%])。
  • 未发现扎维吉泮所致肝毒性信号。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要额外试验来确定长期安全性和跨发作疗效的一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intranasal formulations can provide treatment options for people with migraine in whom oral drugs are ineffective, slow-acting, or intolerable because of nausea and vomiting. Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phase 2/3 trial. This phase 3 trial aimed to compare the efficacy, tolerability, safety, and timecourse of response for zavegepant nasal spray with placebo in the acute treatment of migraine. METHODS: This double-blind, randomised, placebo-controlled, multicentre phase 3 trial, conducted at 90 academic medical centres, headache clinics, and independent research facilities in the USA, recruited adults (aged ≥18 years) with a history of two to eight moderate or severe migraine attacks per month. Participants were randomly assigned (1:1) to zavegepant 10 mg nasal spray or matching placebo and self-treated a single migraine attack of moderate or severe pain intensity. Randomisation was stratified by the use or non-use of preventive medication. Study centre personnel entered eligible participants into the study using an interactive web response system that was operated and managed by an independent contract research organisation. All participants, investigators, and the funder were masked to group assignment. The coprimary endpoints, freedom from pain and freedom from the most bothersome symptom at 2 h after the treatment dose, were assessed in all randomly assigned participants who took the study medication, had a migraine attack of moderate or severe pain intensity at baseline, and provided at least one evaluable post-baseline efficacy datapoint. Safety was analysed in all randomly assigned participants who received at least one dose. The study is registered with ClinicalTrials.gov, number NCT04571060, and is closed to accrual. FINDINGS: Between Oct 27, 2020, and Aug 20, 2021, 1978 participants were recruited and assessed for eligibility. 1405 participants were eligible (703 were assigned to zavegepant and 702 to placebo), and 1269 were included in the efficacy analysis set (623 in the zavegepant group and 646 in the placebo group). 2 h after the treatment dose, more participants in the zavegepant group than in the placebo group had pain freedom (147 [24%] of 623 participants vs 96 [15%] of 646 participants, risk difference 8·8 percentage points, 95% CI 4·5-13·1; p<0·0001) and freedom from their most bothersome symptom (247 [40%] vs 201 [31%], risk difference 8·7 percentage points, 3·4-13·9; p=0·0012). The most common adverse events in either treatment group (≥2%) were dysgeusia (129 [21%] of 629 in the zavegepant group vs 31 [5%] of 653 in the placebo group), nasal discomfort (23 [4%] vs five [1%]), and nausea (20 [3%] vs seven [1%]). No signal of hepatotoxicity due to zavegepant was identified. INTERPRETATION: Zavegepant 10 mg nasal spray was efficacious in the acute treatment of migraine, with favourable tolerability and safety profiles. Additional trials are needed to establish the long-term safety and consistency of effect across attacks. FUNDING: Biohaven Pharmaceuticals.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023. PMID: 36804093. doi:10.1016/S1474-4422(22)00517-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。